Abstract:During normal aging, there is a decline in all physiological functions in the organism. One of the most affected organs is the brain, where neurons lose their proper synaptic function leading to cognitive impairment. Aging is one of the main risk factors for the development of neurodegenerative diseases, such as Alzheimer's disease. One of the main responsible factors for synaptic dysfunction in aging and neurodegenerative diseases is the accumulation of abnormal proteins forming aggregates. The most studied brain aggregates are the senile plaques, formed by Aβ peptide; however, the aggregates formed by phosphorylated tau protein have gained relevance in the last years by their toxicity. It is reported that neurons undergo severe mitochondrial dysfunction with age, with a decrease in adenosine 5'-triphosphate production, loss of the mitochondrial membrane potential, redox imbalance, impaired mitophagy, and loss of calcium buffer capacity. Interestingly, abnormal tau protein interacts with several mitochondrial proteins, suggesting that it could induce mitochondrial dysfunction. Nevertheless, whether tau-mediated mitochondrial dysfunction occurs indirectly or directly is still unknown. A recent study of our laboratory shows that phosphorylated tau at Ser396/404 (known as PHF-1), an epitope commonly related to pathology, accumulates inside mitochondria during normal aging. This accumulation occurs preferentially in synaptic mitochondria, which suggests that it may contribute to the synaptic failure and cognitive impairment seen in aged individuals. Here, we review the main tau modifications promoting mitochondrial dysfunction, and the possible mechanism involved. Also, we discuss the evidence that supports the possibility that phosphorylated tau accumulation in synaptic mitochondria promotes synaptic and cognitive impairment in aging. Finally, we show evidence and argue about the presence of phosphorylated tau PHF-1 inside mitochondria in Alzheimer's disease, which could be considered as an early event in the neurodegenerative process. Thus, phosphorylated tau PHF-1 inside the mitochondria could be considered such a potential therapeutic target to prevent or attenuate age-related cognitive impairment.

Aging device: tau protein transposes the telomere fragment into promoter/enhancer to promote gene copy number decrement regulation

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Telomere Dysfunction of Lymphocytes in Patients with Alzheimer Disease.

Tau Protein Antagonizes Cell Apoptosis Through Akt Pathway

P3‐309: Overexpression of Hyperphosphorylated Tau Antagonizes Aβ‐potentiated Apoptosis with Preservation of Mitochondrial Elements

Aggregation promoting sequences rather than phosphorylation are essential for Tau-mediated toxicity in

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Pathogenic Tau Accelerates Aging-Associated Activation of Transposable Elements in the Mouse Central Nervous System

The Mechanistic Link Between Tau-Driven Proteotoxic Stress and Cellular Senescence in Alzheimer's Disease

Tau Modulates mRNA Transcription, Alternative Polyadenylation Profiles of hnRNPs, Chromatin Remodeling and Spliceosome Complexes

JUMP AROUND, JUMP AROUND: TRANSPOSABLE ELEMENT ACTIVATION IN NEURODEGENERATIVE TAUOPATHY

Pathogenic Tau-Induced Pirna Depletion Promotes Neuronal Death Through Transposable Element Dysregulation in Neurodegenerative Tauopathies

Phosphorylation of Tau Antagonizes Apoptosis by Stabilizing Β-Catenin, a Mechanism Involved in Alzheimer's Neurodegeneration

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease

Aging-associated REGγ proteasome decline predisposes to tauopathy

Broad activation of the PRKN pathway triggers synaptic failure by disrupting synaptic mitochondrial supply in early tauopathy

Phosphorylated tau as a toxic agent in synaptic mitochondria: implications in aging and Alzheimer’s disease

Cleavage of Tau by Asparagine Endopeptidase Mediates the Neurofibrillary Pathology in Alzheimer's Disease

Expression of A152T Human Tau Causes Age‐dependent Neuronal Dysfunction and Loss in Transgenic Mice

The disease-causing tau V337M mutation induces tau hypophosphorylation and perturbs axon morphology pathways

Hyperphosphorylation Results in Tau Dysfunction in DNA Folding and Protection.